Lorenzo Silva-Hernandez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lorenzo Silva-Hernandez has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
A. Guerrero Sola
Servicio de Neurología, Hospital Clínico San Carlos, Madrid, España
1 shared publicationA. Horga Hernández
Servicio de Neurología, Hospital Clínico San Carlos, Madrid, España
1 shared publicationA. Valls Carbó
Servicio de Neurología, Hospital Clínico San Carlos, Madrid, España
1 shared publication- Agnès Ribes
INSERM, UMR1297 and Université Toulouse 3, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Toulouse, France
1 shared publication - Alix Simon
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Inserm U1258, CNRS UMR7104, University of Strasbourg, Illkirch, France
1 shared publication B. Cabal-Paz
Servicio de Neurología, Hospital Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by SMC Media in European Journal of Case Reports in Internal Medicine
- Vol. 13 (10)
Hirayama disease in a patient with Loeys-Dietz syndrome: the first reported association
Introduction: Hirayama disease (HD) is a rare, self-limiting cervical flexion myelopathy causing progressive, painless distal upper-limb weakness, typically in young Asian males. Loeys-Dietz syndrome (LDS) is a heritable connective tissue disorder due to TGF-β pathway variants, associated with dural ectasia. Their co-occurrence has not previously been reported. Case description: We describe a 23-year-old woman with genetically confirmed LDS type 2 who developed progressive, painless distal upper-limb weakness, initially unilateral and later bilateral. Examination and electrophysiology showed a C7–T1 polyradicular pattern. Dynamic flexion cervical magnetic resonance imaging (MRI) demonstrated anterior displacement of the posterior dural sac at C5–C7, fully reversible on extension, confirming HD. Conclusion: This presentation was atypical for HD (female sex, third-decade onset, bilateral course), yet electrophysiological and dynamic-MRI findings were unequivocal. HD should be considered in patients with heritable connective tissue disease presenting with progressive distal upper-limb weakness, irrespective of sex or age, and dynamic flexion MRI is essential for diagnosis.
- 25 September 2026
- Published by SMC Media in European Journal of Case Reports in Internal Medicine
- Vol. 13 (10)
Open AccessHirayama disease in a patient with Loeys-Dietz syndrome: the first reported association
Introduction: Hirayama disease (HD) is a rare, self-limiting cervical flexion myelopathy causing progressive, painless distal upper-limb weakness, typically in young Asian males. Loeys-Dietz syndrome (LDS) is a heritable connective tissue disorder due to TGF-β pathway variants, associated with dural ectasia. Their co-occurrence has not previously been reported. Case description: We describe a 23-year-old woman with genetically confirmed LDS type 2 who developed progressive, painless distal upper-limb weakness, initially unilateral and later bilateral. Examination and electrophysiology showed a C7–T1 polyradicular pattern. Dynamic flexion cervical magnetic resonance imaging (MRI) demonstrated anterior displacement of the posterior dural sac at C5–C7, fully reversible on extension, confirming HD. Conclusion: This presentation was atypical for HD (female sex, third-decade onset, bilateral course), yet electrophysiological and dynamic-MRI findings were unequivocal. HD should be considered in patients with heritable connective tissue disease presenting with progressive distal upper-limb weakness, irrespective of sex or age, and dynamic flexion MRI is essential for diagnosis.
- Open Access
- 25 January 2025
- Published by Elsevier in Neurología (English Edition)
- Vol. 40 (1) , 89-91
Clinical variability in STIM1 variant c.262A>G associated with Stormorken syndrome
- 25 January 2025
- Published by Elsevier in Neurología (English Edition)
- Vol. 40 (1) , 89-91
Open AccessClinical variability in STIM1 variant c.262A>G associated with Stormorken syndrome
- Open Access
- 15 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
ORAI1 inhibition as an efficient preclinical therapy for tubular aggregate myopathy and Stormorken syndrome
Tubular aggregate myopathy (TAM) and Stormorken syndrome (STRMK) are clinically overlapping disorders characterized by childhood-onset muscle weakness and a variable occurrence of multisystemic signs, including short stature, thrombocytopenia, and hyposplenism. TAM/STRMK is caused by gain-of-function mutations in the Ca 2+ sensor STIM1 or the Ca 2+ channel ORAI1, both of which regulate Ca 2+ homeostasis through the ubiquitous store-operated Ca 2+ entry (SOCE) mechanism. Functional experiments in cells have demonstrated that the TAM/STRMK mutations induce SOCE overactivation, resulting in excessive influx of extracellular Ca 2+ . There is currently no treatment for TAM/STRMK, but SOCE is amenable to manipulation. Here, we crossed Stim1 R304W/+ mice harboring the most common TAM/STRMK mutation with Orai1 R93W/+ mice carrying an ORAI1 mutation partially obstructing Ca 2+ influx. Compared with Stim1 R304W/+ littermates, Stim1 R304W/+ Orai1 R93W/+ offspring showed a normalization of bone architecture, spleen histology, and muscle morphology; an increase of thrombocytes; and improved muscle contraction and relaxation kinetics. Accordingly, comparative RNA-Seq detected more than 1,200 dysregulated genes in Stim1 R304W/+ muscle and revealed a major restoration of gene expression in Stim1 R304W/+ Orai1 R93W/+ mice. Altogether, we provide physiological, morphological, functional, and molecular data highlighting the therapeutic potential of ORAI1 inhibition to rescue the multisystemic TAM/STRMK signs, and we identified myostatin as a promising biomarker for TAM/STRMK in humans and mice.
- 15 February 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (6)
Open AccessORAI1 inhibition as an efficient preclinical therapy for tubular aggregate myopathy and Stormorken syndrome
Tubular aggregate myopathy (TAM) and Stormorken syndrome (STRMK) are clinically overlapping disorders characterized by childhood-onset muscle weakness and a variable occurrence of multisystemic signs, including short stature, thrombocytopenia, and hyposplenism. TAM/STRMK is caused by gain-of-function mutations in the Ca 2+ sensor STIM1 or the Ca 2+ channel ORAI1, both of which regulate Ca 2+ homeostasis through the ubiquitous store-operated Ca 2+ entry (SOCE) mechanism. Functional experiments in cells have demonstrated that the TAM/STRMK mutations induce SOCE overactivation, resulting in excessive influx of extracellular Ca 2+ . There is currently no treatment for TAM/STRMK, but SOCE is amenable to manipulation. Here, we crossed Stim1 R304W/+ mice harboring the most common TAM/STRMK mutation with Orai1 R93W/+ mice carrying an ORAI1 mutation partially obstructing Ca 2+ influx. Compared with Stim1 R304W/+ littermates, Stim1 R304W/+ Orai1 R93W/+ offspring showed a normalization of bone architecture, spleen histology, and muscle morphology; an increase of thrombocytes; and improved muscle contraction and relaxation kinetics. Accordingly, comparative RNA-Seq detected more than 1,200 dysregulated genes in Stim1 R304W/+ muscle and revealed a major restoration of gene expression in Stim1 R304W/+ Orai1 R93W/+ mice. Altogether, we provide physiological, morphological, functional, and molecular data highlighting the therapeutic potential of ORAI1 inhibition to rescue the multisystemic TAM/STRMK signs, and we identified myostatin as a promising biomarker for TAM/STRMK in humans and mice.
- Open Access
- 1 March 2023
- Published by Elsevier in Neurología
- Vol. 38 (2) , 87-92
«Red flags» en pacientes con polineuropatía amiloidótica familiar relacionada con transtiretina (hATTR) en el momento del diagnóstico en un área no endémica de España
- 1 March 2023
- Published by Elsevier in Neurología
- Vol. 38 (2) , 87-92
Open Access«Red flags» en pacientes con polineuropatía amiloidótica familiar relacionada con transtiretina (hATTR) en el momento del diagnóstico en un área no endémica de España